BR112022013009A2 - Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina - Google Patents
Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulinaInfo
- Publication number
- BR112022013009A2 BR112022013009A2 BR112022013009A BR112022013009A BR112022013009A2 BR 112022013009 A2 BR112022013009 A2 BR 112022013009A2 BR 112022013009 A BR112022013009 A BR 112022013009A BR 112022013009 A BR112022013009 A BR 112022013009A BR 112022013009 A2 BR112022013009 A2 BR 112022013009A2
- Authority
- BR
- Brazil
- Prior art keywords
- insulin
- increase
- insulin derivative
- pharmaceutical composition
- derivative
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 12
- 239000004026 insulin derivative Substances 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 6
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- -1 GLP-1 compound Chemical class 0.000 abstract 1
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 108010050259 insulin degludec Proteins 0.000 abstract 1
- 229960004225 insulin degludec Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
DERIVADOS DE INSULINA, COMPOSIÇÃO FARMACÊUTICA, USO DO DERIVADO DA INSULINA E MÉTODOS PARA TRATAR OU PREVENIR DIABETES, PARA AUMENTAR A CAPACIDADE DE UM DERIVADO DE INSULINA E PARA AUMENTAR A POTÊNCIA DE UM DERIVADO DE INSULINA. Divulga-se uma insulina acilada, uma formulação farmacêutica, uma composição farmacêutica com um composto GLP-1 de ação prolongada e um uso médico da insulina acilada, da formulação farmacêutica e da composição farmacêutica. Comparada à insulina degludec ou outros derivados de insulina, a insulina acilada tem um efeito inesperado e significativamente aumentado, uma duração de ação mais longa, uma meia-vida in vivo mais longa, uma excelente biodisponibilidade, além de melhores estabilidades física e química.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911398378 | 2019-12-30 | ||
| CN202011057926 | 2020-09-29 | ||
| PCT/CN2020/141023 WO2021136296A1 (zh) | 2019-12-30 | 2020-12-29 | 胰岛素衍生物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013009A2 true BR112022013009A2 (pt) | 2022-09-06 |
Family
ID=76687317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013150A BR112022013150A2 (pt) | 2019-12-30 | 2020-12-29 | Derivado da insulina |
| BR112022013009A BR112022013009A2 (pt) | 2019-12-30 | 2020-12-29 | Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013150A BR112022013150A2 (pt) | 2019-12-30 | 2020-12-29 | Derivado da insulina |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20230126068A1 (pt) |
| EP (3) | EP4086279A4 (pt) |
| JP (2) | JP2023510219A (pt) |
| KR (2) | KR20220119730A (pt) |
| CN (11) | CN118420743A (pt) |
| AU (2) | AU2020418205A1 (pt) |
| BR (2) | BR112022013150A2 (pt) |
| CA (2) | CA3166495A1 (pt) |
| MX (2) | MX2022008174A (pt) |
| WO (3) | WO2021136293A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020418207A1 (en) * | 2019-12-30 | 2022-08-25 | Gan & Lee Pharmaceuticals Co., Ltd. | Long-acting GLP-1 compound |
| JP2023554693A (ja) | 2021-01-20 | 2023-12-28 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| JP2024521757A (ja) * | 2021-05-24 | 2024-06-04 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 新規なアシル化インスリンアナログ |
| CN118139875A (zh) * | 2021-06-25 | 2024-06-04 | 甘李药业股份有限公司 | 含酰化胰岛素的药物组合物 |
| CN116162147B (zh) * | 2021-11-24 | 2023-10-03 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
| CN118574842A (zh) * | 2022-01-28 | 2024-08-30 | 甘李药业股份有限公司 | 酰化胰岛素 |
| WO2024179606A1 (zh) * | 2023-03-02 | 2024-09-06 | 甘李药业股份有限公司 | 一种glp-1化合物的医药用途 |
| CN116327890B (zh) * | 2023-05-29 | 2023-12-08 | 北京先为达生物科技有限公司 | 口服递送的组合物及其应用 |
| CN116789801B (zh) * | 2023-08-21 | 2023-11-14 | 南京赛诺生物技术有限公司 | 新型胰岛素衍生物及其用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ199391A (en) | 1981-01-02 | 1985-12-13 | Genentech Inc | Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin |
| DK58285D0 (da) | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| DK336188D0 (da) | 1988-06-20 | 1988-06-20 | Nordisk Gentofte | Propeptider |
| KR910700262A (ko) | 1988-12-23 | 1991-03-14 | 안네 제케르 | 사람 인슐린 유사체 |
| PT93057B (pt) | 1989-02-09 | 1995-12-29 | Lilly Co Eli | Processo para a preparacao de analogos da insulina |
| UA45321C2 (uk) | 1993-09-17 | 2002-04-15 | Ново Нордіск А/С | Похідне інсуліну, фармацевтична композиція для лікування діабету та спосіб лікування діабету |
| WO1995016708A1 (en) | 1993-12-17 | 1995-06-22 | Novo Nordisk A/S | Proinsulin-like compounds |
| US6500645B1 (en) | 1994-06-17 | 2002-12-31 | Novo Nordisk A/S | N-terminally extended proteins expressed in yeast |
| KR0150565B1 (ko) | 1995-02-15 | 1998-08-17 | 김정재 | 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법 |
| WO1996034882A1 (en) | 1995-05-05 | 1996-11-07 | Eli Lilly And Company | Single chain insulin with high bioactivity |
| PL2107069T3 (pl) | 2003-08-05 | 2013-06-28 | Novo Nordisk As | Nowe pochodne insuliny |
| ES2542146T3 (es) | 2006-07-31 | 2015-07-31 | Novo Nordisk A/S | Insulinas extendidas PEGiladas. |
| CN101743252A (zh) | 2007-07-16 | 2010-06-16 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定化的、peg化的胰岛素类似物 |
| KR20100053561A (ko) * | 2007-08-15 | 2010-05-20 | 노보 노르디스크 에이/에스 | 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체 |
| EP2178910B1 (en) * | 2007-08-15 | 2014-10-08 | Novo Nordisk A/S | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids |
| JP2010538049A (ja) * | 2007-09-05 | 2010-12-09 | ノボ・ノルデイスク・エー／エス | 切断型ｇｌｐ−１誘導体及びその治療的使用 |
| EP2910569B1 (en) * | 2008-03-18 | 2016-10-05 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
| EP2720711A1 (en) * | 2011-06-15 | 2014-04-23 | Novo Nordisk A/S | Multi substituted insulins |
| CN104788556A (zh) | 2011-12-15 | 2015-07-22 | 上海恒瑞医药有限公司 | 人胰岛素类似物及其酰化衍生物 |
| US20150111820A1 (en) * | 2012-07-09 | 2015-04-23 | Novo Nordisk A/S | Novel use of insulin derivatives |
| CN105820233B (zh) | 2015-01-04 | 2021-06-15 | 甘李药业股份有限公司 | 一种胰岛素衍生物的制备方法 |
| JP6737793B2 (ja) * | 2015-01-29 | 2020-08-12 | ノヴォ ノルディスク アー／エス | 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物 |
| US11352406B2 (en) * | 2015-08-25 | 2022-06-07 | Novo Nordisk A/S | Insulin derivatives and the medical uses hereof |
| PL3341991T3 (pl) * | 2015-08-27 | 2020-11-30 | Haldor Topsøe A/S | Materiał aktywny litowej elektrody dodatniej o wysokiej gęstości nasypowej z usadem, półprodukt i sposób wytwarzania |
| TWI747929B (zh) * | 2016-08-02 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種人胰島素或其類似物的醯化衍生物 |
| JP6690062B2 (ja) * | 2016-12-16 | 2020-04-28 | ノヴォ ノルディスク アー／エス | インスリン含有医薬組成物 |
| JOP20190273A1 (ar) * | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
-
2020
- 2020-12-29 EP EP20910566.7A patent/EP4086279A4/en active Pending
- 2020-12-29 WO PCT/CN2020/141018 patent/WO2021136293A1/zh unknown
- 2020-12-29 CN CN202410254314.8A patent/CN118420743A/zh active Pending
- 2020-12-29 CN CN202080091196.3A patent/CN114901682B/zh active Active
- 2020-12-29 BR BR112022013150A patent/BR112022013150A2/pt unknown
- 2020-12-29 US US17/758,089 patent/US20230126068A1/en active Pending
- 2020-12-29 BR BR112022013009A patent/BR112022013009A2/pt unknown
- 2020-12-29 CN CN202410312576.5A patent/CN118666989A/zh active Pending
- 2020-12-29 EP EP20908882.2A patent/EP4086278A4/en active Pending
- 2020-12-29 KR KR1020227026305A patent/KR20220119730A/ko unknown
- 2020-12-29 KR KR1020227024018A patent/KR20220121833A/ko active Search and Examination
- 2020-12-29 US US17/758,101 patent/US20240239862A1/en active Pending
- 2020-12-29 CA CA3166495A patent/CA3166495A1/en active Pending
- 2020-12-29 WO PCT/CN2020/141056 patent/WO2021136302A1/zh unknown
- 2020-12-29 CN CN202080091153.5A patent/CN114901681B/zh active Active
- 2020-12-29 CN CN202410286752.2A patent/CN118598978A/zh active Pending
- 2020-12-29 WO PCT/CN2020/141023 patent/WO2021136296A1/zh unknown
- 2020-12-29 MX MX2022008174A patent/MX2022008174A/es unknown
- 2020-12-29 CN CN202410254905.5A patent/CN118420744A/zh active Pending
- 2020-12-29 CN CN202410312489.XA patent/CN118480114A/zh active Pending
- 2020-12-29 JP JP2022540871A patent/JP2023510219A/ja active Pending
- 2020-12-29 EP EP20910739.0A patent/EP4086280A4/en active Pending
- 2020-12-29 US US17/758,108 patent/US20240025957A1/en active Pending
- 2020-12-29 CN CN202410288928.8A patent/CN118206632A/zh active Pending
- 2020-12-29 AU AU2020418205A patent/AU2020418205A1/en active Pending
- 2020-12-29 JP JP2022540767A patent/JP2023510206A/ja active Pending
- 2020-12-29 CA CA3166494A patent/CA3166494A1/en active Pending
- 2020-12-29 AU AU2020417892A patent/AU2020417892A1/en active Pending
- 2020-12-29 CN CN202411113581.XA patent/CN118754967A/zh active Pending
- 2020-12-29 MX MX2022008130A patent/MX2022008130A/es unknown
- 2020-12-29 CN CN202411113751.4A patent/CN118772259A/zh active Pending
- 2020-12-29 CN CN202080091328.2A patent/CN114901683B/zh active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022013009A2 (pt) | Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina | |
| BR112023024646A2 (pt) | Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina | |
| AR110986A2 (es) | Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso | |
| AR054234A1 (es) | Composicion farmaceutica para el tratamiento del cancer | |
| DE602006014990D1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
| CY1111159T1 (el) | Πυκνα διαλυματα μεθοτρεξατης | |
| BRPI0615860B8 (pt) | composição farmacêutica de liberação prolongada monolítica sólida | |
| AR049518A1 (es) | Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados | |
| BR112012026255A2 (pt) | composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas | |
| AR094548A1 (es) | Dispersión sólida físicamente estable | |
| EA201490489A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
| BR112015017246A8 (pt) | composição farmacêutica aquosa, seu uso e seringa | |
| EA201792487A1 (ru) | Композиции гидроксипропил-бета-циклодекстринов и способы | |
| BR112016001544A8 (pt) | composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório | |
| PH12019501363A1 (en) | Insulin containing pharmaceutical compositions | |
| PH12019502655A1 (en) | Acylated insulin compound | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| BR112018002416A2 (pt) | derivados de insulina e seus usos médicos | |
| MX2022014309A (es) | Compuestos de insulina acilada de accion temporal prolongada. | |
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
| PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
| BRPI0700133A (pt) | composição farmacêutica compreendendo tramadol e cetoprofeno em combinação | |
| BR112021025291A2 (pt) | Dispositivos de contenção de medicamento e composições associadas | |
| BRPI0815280A2 (pt) | medicamento que compreende uma formulação líquida aquosa de g-csf, receptáculo para a administração de medicamentos líquidos, seringa ou ampola, kit para a administração parenteral de g-csf |